仿制药-话题@MedSci

#仿制药#

261篇内容 | 5516人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261534, encodeId=16f61261534b7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=瑞德西韦仿制药获批，定价公布, objectType=article, longId=196356, objectId=b630196356ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b630196356ec, replyNumber=0, likeNumber=102, createdTime=2020-06-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b630196356ec, moduleTitle=瑞德西韦仿制药获批，定价公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b630196356ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261533, encodeId=9162126153387, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, objectType=article, longId=195153, objectId=438319515359, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438319515359, replyNumber=0, likeNumber=0, createdTime=2020-06-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438319515359, moduleTitle=中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438319515359)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261532, encodeId=25701261532da, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果, objectType=article, longId=194134, objectId=23531941348f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23531941348f, replyNumber=0, likeNumber=73, createdTime=2020-05-15, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23531941348f, moduleTitle=“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23531941348f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261531, encodeId=7619126153123, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=吉利德：将在多国产销瑞德西韦，正与印巴药商谈判仿制药许可, objectType=article, longId=193588, objectId=354719358855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=354719358855, replyNumber=0, likeNumber=0, createdTime=2020-05-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=354719358855, moduleTitle=吉利德：将在多国产销瑞德西韦，正与印巴药商谈判仿制药许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=354719358855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261530, encodeId=700e12615306a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, objectType=article, longId=191859, objectId=6d7f19185941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7f19185941, replyNumber=0, likeNumber=95, createdTime=2020-04-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7f19185941, moduleTitle=FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7f19185941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261529, encodeId=a51212615295f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, objectType=article, longId=191492, objectId=9a9c19149256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9c19149256, replyNumber=0, likeNumber=68, createdTime=2020-04-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9c19149256, moduleTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9c19149256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261528, encodeId=39cf12615285d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市, objectType=article, longId=189494, objectId=e7f118949412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7f118949412, replyNumber=0, likeNumber=79, createdTime=2020-03-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7f118949412, moduleTitle=在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7f118949412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261527, encodeId=0cf8126152ee4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病, objectType=article, longId=188087, objectId=b4a918808ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a918808ec8, replyNumber=0, likeNumber=48, createdTime=2020-02-16, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a918808ec8, moduleTitle=2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a918808ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261526, encodeId=22f81261526a4, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, objectType=article, longId=187232, objectId=b01918e23299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01918e23299, replyNumber=0, likeNumber=64, createdTime=2020-02-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01918e23299, moduleTitle=辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01918e23299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261525, encodeId=40951261525e0, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=药有不同，原研药与仿制药大解析, objectType=article, longId=185339, objectId=e0351853396d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0351853396d, replyNumber=0, likeNumber=73, createdTime=2019-12-29, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0351853396d, moduleTitle=药有不同，原研药与仿制药大解析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0351853396d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261524, encodeId=e6c51261524f9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=阿哌沙班的仿制药在美国获批, objectType=article, longId=185149, objectId=2d0d1851498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0d1851498a, replyNumber=0, likeNumber=63, createdTime=2019-12-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0d1851498a, moduleTitle=阿哌沙班的仿制药在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0d1851498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261523, encodeId=45bc1261523da, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=原研药、仿制药怎么选？药学专家崔永耀这样建议, objectType=article, longId=184921, objectId=d37e18492195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d37e18492195, replyNumber=0, likeNumber=68, createdTime=2019-12-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d37e18492195, moduleTitle=原研药、仿制药怎么选？药学专家崔永耀这样建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d37e18492195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261522, encodeId=c805126152205, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2019 立场声明：应用生物仿制药治疗炎症性肠病, objectType=article, longId=184712, objectId=e6d4184e1243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6d4184e1243, replyNumber=0, likeNumber=42, createdTime=2019-12-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6d4184e1243, moduleTitle=2019 立场声明：应用生物仿制药治疗炎症性肠病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6d4184e1243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261521, encodeId=c947126152183, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, objectType=article, longId=184300, objectId=0ae61843008b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae61843008b, replyNumber=0, likeNumber=66, createdTime=2019-12-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae61843008b, moduleTitle=FDA批准了诺华多发性硬化症药物Gilenya的仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae61843008b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261520, encodeId=97ff126152099, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=修美乐第二个国产仿制药获批在即, objectType=article, longId=184177, objectId=68071841e724, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68071841e724, replyNumber=0, likeNumber=60, createdTime=2019-12-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68071841e724, moduleTitle=修美乐第二个国产仿制药获批在即, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68071841e724)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261519, encodeId=57051261519af, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, objectType=article, longId=183993, objectId=3c02183993a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c02183993a4, replyNumber=0, likeNumber=67, createdTime=2019-12-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c02183993a4, moduleTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c02183993a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261518, encodeId=61f812615181d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=官方：仿制药一致性评价工作进入常态已审评通过123个品种, objectType=article, longId=183731, objectId=1fbf183e316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fbf183e316b, replyNumber=0, likeNumber=61, createdTime=2019-11-30, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fbf183e316b, moduleTitle=官方：仿制药一致性评价工作进入常态已审评通过123个品种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fbf183e316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261517, encodeId=52bc126151e8c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, objectType=article, longId=183554, objectId=f33d18355468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33d18355468, replyNumber=0, likeNumber=66, createdTime=2019-11-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33d18355468, moduleTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33d18355468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261516, encodeId=24d112615163e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Clin Gastroenterology H：炎症性肠病患者使用生物制剂仿制药的效果分析, objectType=article, longId=183174, objectId=8e611831e42e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e611831e42e, replyNumber=0, likeNumber=62, createdTime=2019-11-20, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e611831e42e, moduleTitle=Clin Gastroenterology H：炎症性肠病患者使用生物制剂仿制药的效果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e611831e42e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261515, encodeId=4bfa126151598, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=恒瑞医药来曲唑片通过仿制药一致性评价, objectType=article, longId=182568, objectId=721418256882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=721418256882, replyNumber=0, likeNumber=55, createdTime=2019-11-09, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=721418256882, moduleTitle=恒瑞医药来曲唑片通过仿制药一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=721418256882)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

瑞德西韦仿制药获批，定价公布

2020-06-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

中国生物仿制药出海：曲妥珠单抗生物仿制药HLX02获CHMP正面评价

2020-06-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

“药王”阿达木单抗再遇劲敌：生物仿制药AVT02取得积极结果

2020-05-15

drwjr (审核中...)

前往app查看评论内容

#仿制药#

吉利德：将在多国产销瑞德西韦，正与印巴药商谈判仿制药许可

2020-05-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准了默克Proventil HFA（硫酸沙丁胺醇）气雾剂的仿制药，用于儿童支气管痉挛

2020-04-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准

2020-04-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

在弓形虫病药物Daraprim价格上涨5000%后，FDA批准了其仿制药上市

2020-03-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2020 CAG/CCC立场声明：生物仿制药治疗炎症性肠病

2020-02-16

drwjr (审核中...)

前往app查看评论内容

#仿制药#

辉瑞的美罗华仿制药RUXIENCE的营销申请，获得欧盟人用药物委员会的积极评价

2020-02-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

药有不同，原研药与仿制药大解析

2019-12-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

阿哌沙班的仿制药在美国获批

2019-12-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

原研药、仿制药怎么选？药学专家崔永耀这样建议

2019-12-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2019 立场声明：应用生物仿制药治疗炎症性肠病

2019-12-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准了诺华多发性硬化症药物Gilenya的仿制药

2019-12-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

修美乐第二个国产仿制药获批在即

2019-12-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎

2019-12-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

官方：仿制药一致性评价工作进入常态已审评通过123个品种

2019-11-30

drwjr (审核中...)

前往app查看评论内容

#仿制药#

2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2019-11-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Clin Gastroenterology H：炎症性肠病患者使用生物制剂仿制药的效果分析

2019-11-20

drwjr (审核中...)

前往app查看评论内容

#仿制药#

恒瑞医药来曲唑片通过仿制药一致性评价

2019-11-09

科室
- - 订阅+
  - 更多科室
工具
服务